We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avantor Expands Masterflex Portfolio to Streamline Bioprocessing
Read MoreHide Full Article
Key Takeaways
Avantor expands Masterflex to unify pumps, assemblies and systems for streamlined fluid handling workflows.
AVTR aims to simplify customization and improve scalability from development to full production stages.
Integrated systems and PROFINET connectivity enhance efficiency and support bioprocessing growth demand.
Avantor, Inc. (AVTR - Free Report) recently announced a strategic expansion of its Masterflex brand across its fluid handling portfolio. The expansion integrates standard, configurable and engineered-to-order peristaltic pumps, single-use assemblies and fluid management systems to streamline fluid handling from early-stage R&D to large-scale manufacturing.
Per management, the Masterflex brand has long represented precision and reliability in peristaltic pump technology. By consolidating its fluid handling portfolio under this brand, AVTR aims to simplify solution customization for customers, enabling a cohesive approach to process design and a smoother progression from development stages to full-scale production.
Likely Trend of AVTR Stock Following the News
Following the announcement, AVTR shares gained 0.4% at yesterday’s closing. In the year-to-date period, shares of the company have declined 25.5% compared with the industry’s 9.4% drop. However, the S&P 500 has risen 4% in the same timeframe.
The expansion positions Avantor for stronger growth by catering to the growing demand for connected, scalable and efficient bioprocessing solutions. Unifying offerings under the Masterflex brand enhances customer experience, while integrated systems increase operational efficiency. This can drive higher adoption, deepen customer relationships and expand revenue opportunities across development and production workflows, strengthening Avantor’s competitive position in the growing bioprocessing market.
AVTR currently has a market capitalization of $5.80 billion.
Image Source: Zacks Investment Research
More on Scalable Bioprocessing Solutions
The Masterflex solutions focus on secure fluid transfer and dependable connections while delivering consistent performance for scalability. With PROFINET-enabled connectivity, the portfolio allows seamless integration between Masterflex peristaltic pumps and process control systems. Avantor has further introduced purpose-built storage containers to improve safety and efficiency in fluid transfer operations.
This expansion aligns with Avantor’s broader strategy of delivering end-to-end bioprocessing solutions. When combined with its J.T. Baker high-purity process chemicals, these offerings create a unified bioprocessing approach.
Live at INTERPHEX 2026
The company is showcasing these advancements at INTERPHEX 2026 in New York City from April 21-23. Attendees can experience fully operational integrated fluid management systems, including tangential flow filtration, storage and pump technologies that demonstrate scalability from lab to production.
Additionally, Zeiny Aubdoollah, Scientist, R&D Applications at Avantor, will deliver a technical session highlighting how fluid handling technologies support performance, along with the latest data demonstrating the scalability of Avantor Magnetic Mixers.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the fluid management systems market is valued at $12.3 billion in 2026 and is expected to witness a CAGR of 5.5% through 2034.
Factors such as the increasing demand for automated infusion monitoring, enhanced patient safety and efficient management of intravenous fluids and medications in hospitals and clinics are enhancing the market expansion.
Other News
Avantor recently announced the expansion of its North American quality control capabilities with advanced microbial and stability testing at its St. Louis facility. The expansion strengthens its U.S. biomanufacturing infrastructure and brings critical testing capabilities closer to customers, reducing reliance on third-party labs and cross-border sample movement.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted earnings per share (EPS) of $1.28 per share, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $826.4 million beat the Zacks Consensus Estimate by 4.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED an estimated long-term earnings growth rate of 9.6% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in three of the trailing four quarters and missed one, the average surprise being 18.8%.
Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Avantor Expands Masterflex Portfolio to Streamline Bioprocessing
Key Takeaways
Avantor, Inc. (AVTR - Free Report) recently announced a strategic expansion of its Masterflex brand across its fluid handling portfolio. The expansion integrates standard, configurable and engineered-to-order peristaltic pumps, single-use assemblies and fluid management systems to streamline fluid handling from early-stage R&D to large-scale manufacturing.
Per management, the Masterflex brand has long represented precision and reliability in peristaltic pump technology. By consolidating its fluid handling portfolio under this brand, AVTR aims to simplify solution customization for customers, enabling a cohesive approach to process design and a smoother progression from development stages to full-scale production.
Likely Trend of AVTR Stock Following the News
Following the announcement, AVTR shares gained 0.4% at yesterday’s closing. In the year-to-date period, shares of the company have declined 25.5% compared with the industry’s 9.4% drop. However, the S&P 500 has risen 4% in the same timeframe.
The expansion positions Avantor for stronger growth by catering to the growing demand for connected, scalable and efficient bioprocessing solutions. Unifying offerings under the Masterflex brand enhances customer experience, while integrated systems increase operational efficiency. This can drive higher adoption, deepen customer relationships and expand revenue opportunities across development and production workflows, strengthening Avantor’s competitive position in the growing bioprocessing market.
AVTR currently has a market capitalization of $5.80 billion.
Image Source: Zacks Investment Research
More on Scalable Bioprocessing Solutions
The Masterflex solutions focus on secure fluid transfer and dependable connections while delivering consistent performance for scalability. With PROFINET-enabled connectivity, the portfolio allows seamless integration between Masterflex peristaltic pumps and process control systems. Avantor has further introduced purpose-built storage containers to improve safety and efficiency in fluid transfer operations.
This expansion aligns with Avantor’s broader strategy of delivering end-to-end bioprocessing solutions. When combined with its J.T. Baker high-purity process chemicals, these offerings create a unified bioprocessing approach.
Live at INTERPHEX 2026
The company is showcasing these advancements at INTERPHEX 2026 in New York City from April 21-23. Attendees can experience fully operational integrated fluid management systems, including tangential flow filtration, storage and pump technologies that demonstrate scalability from lab to production.
Additionally, Zeiny Aubdoollah, Scientist, R&D Applications at Avantor, will deliver a technical session highlighting how fluid handling technologies support performance, along with the latest data demonstrating the scalability of Avantor Magnetic Mixers.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the fluid management systems market is valued at $12.3 billion in 2026 and is expected to witness a CAGR of 5.5% through 2034.
Factors such as the increasing demand for automated infusion monitoring, enhanced patient safety and efficient management of intravenous fluids and medications in hospitals and clinics are enhancing the market expansion.
Other News
Avantor recently announced the expansion of its North American quality control capabilities with advanced microbial and stability testing at its St. Louis facility. The expansion strengthens its U.S. biomanufacturing infrastructure and brings critical testing capabilities closer to customers, reducing reliance on third-party labs and cross-border sample movement.
Avantor, Inc. Price
Avantor, Inc. price | Avantor, Inc. Quote
AVTR’s Zacks Rank & Key Picks
Currently, AVTR has a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted earnings per share (EPS) of $1.28 per share, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $826.4 million beat the Zacks Consensus Estimate by 4.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED an estimated long-term earnings growth rate of 9.6% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in three of the trailing four quarters and missed one, the average surprise being 18.8%.
Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.